# Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

> **NCT00846365** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 1085 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Azilsartan medoxomil and chlorthalidone
- **DRUG:** Azilsartan medoxomil and chlorthalidone
- **DRUG:** Olmesartan medoxomil-hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00846365
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 1085 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00846365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00846365, "Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00846365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*